Supplementary materials: Cortistatin as a novel multimodal therapy for the treatment of Parkinson´s Disease

Supplementary Figure S1. Cortistatin protects against dopaminergic-related toxicity induced by MPTP. -- Supplementary Figure S2. Cortistatin preserves Bdnf expression in the acute model of MPTP. -- Supplementary Figure S3. Treatment with cortistatin reduces MPTP-induced nigral astrogliosis. -- Suppl...

Descripción completa

Detalles Bibliográficos
Autores: Serrano-Martínez, Ignacio, Pedreño, Marta, Castillo-González, Julia, Ferraz-de-Paula, Viviane, Vargas-Rodríguez, Pablo, Forte-Lago, Irene, Caro, Marta, Campos-Salinas, Jenny, Villadiego, Javier, Peñalver, Pablo, Morales, Juan Carlos, Delgado, Mario, González-Rey, Elena
Tipo de recurso: conjunto de datos
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/384733
Acceso en línea:http://hdl.handle.net/10261/384733
Access Level:acceso abierto
Palabra clave:Cortistatin
Neurodegenerative diseases
Neuroinflammation
Parkinson’s disease
Gliosis
Descripción
Sumario:Supplementary Figure S1. Cortistatin protects against dopaminergic-related toxicity induced by MPTP. -- Supplementary Figure S2. Cortistatin preserves Bdnf expression in the acute model of MPTP. -- Supplementary Figure S3. Treatment with cortistatin reduces MPTP-induced nigral astrogliosis. -- Supplementary Figure S4. Cortistatin reduces MPTP-induced reactive microglia in the SNpc. -- Supplementary Figure S5. Cortistatin administration modulates microglia morphotypes in brain regions affected by MPTP. -- Supplementary Figure S6. Schematic representation of microglia-specific morphological prints. -- Table S1. Sequence of primers used for real-time PCR quantifications.

Similares en LA Referencia